Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Cited by 143 Publications

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )
Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )
Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )
Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )
Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )
Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MV\BcpRqdWmlcn;ibYFtKEG\|c3H5		NI\aN\|EyQCCq	MVPEUXNQ	MlLLRY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTD3bZRpKEWFNUCgc4YhOC5yMEK1JO69VQ>?	NF;yNGozPDhyNUm0Oi=>
MCF7	NEDSU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSwMlAyNTFyMDFOwG0>	MYO0PEBp	Mme2SG1UVw>?	NXPoR5ZIUUN3ME2wMlc{KM7:TR?=	MXOyN\|g4OTlyNB?=
HCT116	M3HuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DKSlAvODFvMUCwJO69VQ>?	MX20PEBp	M325bGROW09?	NHTrdpFKSzVyPUGuNVYh\|ryP	NXX4NGlYOjN6N{G5NFQ>
U87MG	NVraNXBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;vXIcxNjBzLUGwNEDPxE1?	NYLOUYJTPDhiaB?=	MXnEUXNQ	MkLMTWM2OD1zLkOyJO69VQ>?	NEDPUXczOzh5MUmwOC=>
HBC4	NFPJVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXKwMlAyNTFyMDFOwG0>	MUG0PEBp		MnX0UI9oKEeLNUC9MVgvPjFiTR?=	MkPwNlI{OzZ{NE[=
BSY1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVr6VoFzOC5yMT2xNFAh\|ryP	MWC0PEBp		MmPaUI9oKEeLNUC9MVgvPDhiTR?=	M{fRZVIzOzN4MkS2
HBC5	NIfOc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[yWG5oOC5yMT2xNFAh\|ryP	MVG0PEBp		NE\Jd3lNd2diR1m1NF0uPy56NzDN	MUGyNlM{PjJ2Nh?=
MCF7	M4n3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\XSnAxNjBzLUGwNEDPxE1?	NYW2WGkxPDhiaB?=		M3TmXWxw\yCJSUWwQU05NjF4IF2=	NV63c4FVOjJ\|M{[yOFY>
MDA-MB-231	NG\UdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlq4NE4xOS1zMECg{txO	NXjzU\|JYPDhiaB?=		NIDoeIxNd2diR1m1NF0uQC5yOTDN	MUeyNlM{PjJ2Nh?=
U251	NVH3fYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYiwMlAyNTFyMDFOwG0>	M3vX[VQ5KGh?		M3jl[mxw\yCJSUWwQU04NjZ4IF2=	NIP1ZXIzOjN\|NkK0Oi=>
SF268	MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXKwMlAyNTFyMDFOwG0>	MkjhOFghcA>?		NXTCVms5VG:pIFfJOVA:NTdwOUKgUS=>	NYfE[mxCOjJ\|M{[yOFY>
SF295	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV2wMlAyNTFyMDFOwG0>	MnvtOFghcA>?		MV7Mc4chT0l3ME2tPE4{OSCP	MUeyNlM{PjJ2Nh?=
SF539	M3Tz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWqwMlAyNTFyMDFOwG0>	NETRTpY1QCCq		M1LzbWxw\yCJSUWwQU05NjV7IF2=	M2LNXFIzOzN4MkS2
SNB75	MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXmNE4xOS1zMECg{txO	NFvSSlM1QCCq		NH\u[5BNd2diR1m1NF0uQC53ODDN	MoL5NlI{OzZ{NE[=
SNB78	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HlbFAvODFvMUCwJO69VQ>?	NIm4cHY1QCCq		NWHX[Il1VG:pIFfJOVA:NThwNkWgUS=>	M2To[\|IzOzN4MkS2
HCC2998	NUnINoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoT1NE4xOS1zMECg{txO	MmLqOFghcA>?		NWHlUldxVG:pIFfJOVA:NThwMEWgUS=>	M4G0S\|IzOzN4MkS2
KM12	NVvB[HZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGwMlAyNTFyMDFOwG0>	M{DFe\|Q5KGh?		MXXMc4chT0l3ME2tO{42PCCP	MX2yNlM{PjJ2Nh?=
HT-29	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;wc2sxNjBzLUGwNEDPxE1?	NHv3bGg1QCCq		M{fIPGxw\yCJSUWwQU04Njd3IF2=	M3\PcFIzOzN4MkS2
HCT15	NWHxR3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjWNE4xOS1zMECg{txO	NI[zPZU1QCCq		M3XQ[Wxw\yCJSUWwQU05NjB\|IF2=	NH;5[pgzOjN\|NkK0Oi=>
HCT116	NUXHWYNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSwMlAyNTFyMDFOwG0>	NULDSmw5PDhiaB?=		M3\3UGxw\yCJSUWwQU04NjZzIF2=	Ml;vNlI{OzZ{NE[=
NCI-H23	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\3RlAvODFvMUCwJO69VQ>?	NFXBXGM1QCCq		NYXrVlhrVG:pIFfJOVA:NTdwNkSgUS=>	MljzNlI{OzZ{NE[=
NCI-H226	NWnEXpk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYqwMlAyNTFyMDFOwG0>	MYK0PEBp		NFL6[HFNd2diR1m1NF0uQC52NDDN	Mo\HNlI{OzZ{NE[=
NCI-H522	NIrZT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\Kfm4xNjBzLUGwNEDPxE1?	MVu0PEBp		MmnUUI9oKEeLNUC9MVgvPDViTR?=	M1;yclIzOzN4MkS2
NCI-H438	NXjlZmtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHP0TFExNjBzLUGwNEDPxE1?	NHnCTlY1QCCq		Mki3UI9oKEeLNUC9MVgvOTFiTR?=	M2HzSVIzOzN4MkS2
A549	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7jNE4xOS1zMECg{txO	NIW1cIQ1QCCq		NUC3bnpRVG:pIFfJOVA:NThwMEegUS=>	NH2wNHUzOjN\|NkK0Oi=>
DMS273	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:wdngxNjBzLUGwNEDPxE1?	NWrFfYx7PDhiaB?=		NIO0cI5Nd2diR1m1NF0uPy56MDDN	M{Xoe\|IzOzN4MkS2
DMS114	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPiNE4xOS1zMECg{txO	MXe0PEBp		MY\Mc4chT0l3ME2tPE4{QSCP	MV:yNlM{PjJ2Nh?=
LOXIMVI	M33LZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\UWFgxNjBzLUGwNEDPxE1?	NIK2TGM1QCCq		Mn;GUI9oKEeLNUC9MVgvPjZiTR?=	M2\YZlIzOzN4MkS2
OVCAR3	M4LnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVWzO5BmOC5yMT2xNFAh\|ryP	M2LD[FQ5KGh?		Mkn0UI9oKEeLNUC9MVgvOTdiTR?=	MnrFNlI{OzZ{NE[=
OVCAR4	MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH0NE4xOS1zMECg{txO	MmfMOFghcA>?		NHizO2ZNd2diR1m1NF0uQC53ODDN	M370V\|IzOzN4MkS2
OVCAR5	M2S0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjVO\|AxNjBzLUGwNEDPxE1?	NUP4cJI6PDhiaB?=		NYXGS5RUVG:pIFfJOVA:NTdwNUegUS=>	MUSyNlM{PjJ2Nh?=
OVCAR8	NF;ybmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\n[nYxNjBzLUGwNEDPxE1?	NGX4XVY1QCCq		NF3hVHpNd2diR1m1NF0uPy56NDDN	M2HBUlIzOzN4MkS2
SKOV3	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVr6Vm96OC5yMT2xNFAh\|ryP	NX36SoY4PDhiaB?=		NETrOlRNd2diR1m1NF0uQC52MTDN	NUfGVGtmOjJ\|M{[yOFY>
RXF631L	M2TIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG0NE4xOS1zMECg{txO	M1;ndVQ5KGh?		MmXVUI9oKEeLNUC9MVgvOjFiTR?=	MXSyNlM{PjJ2Nh?=
ACHN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGwMlAyNTFyMDFOwG0>	M{LxTlQ5KGh?		NH7TVHBNd2diR1m1NF0uPy57NTDN	NVrRbWg3OjJ\|M{[yOFY>
St-4	NUm5VpNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;jNE4xOS1zMECg{txO	NXL2VndIPDhiaB?=		M2DOVGxw\yCJSUWwQU04NjR5IF2=	NH:zVFMzOjN\|NkK0Oi=>
MKN1	M2DBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuwMlAyNTFyMDFOwG0>	MkjNOFghcA>?		NVO3TJlkVG:pIFfJOVA:NThwNEGgUS=>	MWqyNlM{PjJ2Nh?=
MKN7	NGe2e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnRNE4xOS1zMECg{txO	NYXHSoN4PDhiaB?=		NX;jRlZZVG:pIFfJOVA:NTdwNkigUS=>	MWiyNlM{PjJ2Nh?=
MKN28	M{PuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLqNE4xOS1zMECg{txO	Mn7POFghcA>?		MWPMc4chT0l3ME2tO{4xPyCP	MlfyNlI{OzZ{NE[=
MKN45	M1r4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULqUot4OC5yMT2xNFAh\|ryP	M2LRWlQ5KGh?		M4PjZmxw\yCJSUWwQU05NjN2IF2=	M{n5bFIzOzN4MkS2
MKN74	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLHNGcxOC5yMT2xNFAh\|ryP	NFLjflc1QCCq		NVK2cmh4VG:pIFfJOVA:NTdwNEKgUS=>	MV6yNlM{PjJ2Nh?=
DU145	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDINE4xOS1zMECg{txO	MlHtOFghcA>?		NH75fmtNd2diR1m1NF0uQC5zNjDN	M3nhflIzOzN4MkS2
PC3	NWXzbG57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWiwMlAyNTFyMDFOwG0>	NH2zWWo1QCCq		NH7WXnpNd2diR1m1NF0uQC54NjDN	MUGyNlM{PjJ2Nh?=
Trypanosoma brucei brucei	Mli2SpVv[3Srb36gRZN{[Xl?	NIPpT2IzODBibl2=	NWTwdmNxOTJiaB?=	NW\vPYQ{TE2VTx?=	MYfE[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	NIXLUnozPDhyNUm0Oi=>
Trypanosoma brucei brucei	NELTUGZHfW6ldHnvckBCe3OjeR?=		M3zhb\|E5KGh?	M1HvR2ROW09?	MWXJcohq[mm2aX;uJI9nKHKnY3XweI9zNW2nZHnheIVlKGWwZH;jfZRwe2m\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHS{YX7z[oVzemmwIIXweIFs\Q>?	M3n4dVI1QDB3OUS2
Trypanosoma brucei brucei	M{TBVGZ2dmO2aX;uJGF{e2G7	NXuySHZXOjByIH7N	M1OyWFEzKGh?	NUHVSGVKTE2VTx?=	MWDF[oZm[3Rib36gd5BpcW6pb335cIVqdiCuZY\lcC=>	NUHzOVBzOjR6MEW5OFY>
Trypanosoma brucei brucei	MU\GeY5kfGmxbjDBd5NigQ>?	MUeyNFAhdk1?	NX6zPHN{OTJiaB?=	NHi0co9FVVOR	NF[wc4RG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>	MkjpNlQ5ODV7NE[=
UM-UC-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjpU\|VZUUN3ME2zNVUheE1?	MVjTRW5ITVJ?
SBC-1	NUXSS2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vTR2lEPTB;N{SyJJBO	MYDTRW5ITVJ?
MKN1	NWXBSJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTsTWM2OD1{Lkigcm0>	NGXtOnhUSU6JRWK=
NCI-H720	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPmfY9KSzVyPUOuOVchdk1?	MlTSV2FPT0WU
BFTC-909	NEPDbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTwTWM2OD1\|LkexJI5O	NGGxb3dUSU6JRWK=
BPH-1	M2nVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\MTWM2OD12Lke2JI5O	MVTTRW5ITVJ?
PC-3	NV:yc2hlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq3TWM2OD13LkC5JI5O	NUCxNoFqW0GQR1XS
AN3-CA	M3TFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYf6WGZ2UUN3ME21MlU3KG6P	NH\1W\|RUSU6JRWK=
HN	NUnY[VhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXR[WNKSzVyPUWuPVYhdk1?	NHnyfotUSU6JRWK=
HCC2218	M{TER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjOb2w1UUN3ME22MlYyKG6P	M4T3N3NCVkeHUh?=
KP-4	NFnJRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M123NmlEPTB;NzDuUS=>	M1nP[nNCVkeHUh?=
LU-139	MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXMTG9IUUN3ME23Mlc4KG6P	MVPTRW5ITVJ?
ETK-1	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXLV5d[UUN3ME23Mlg5KG6P	NYW1WHRyW0GQR1XS
Ramos-2G6-4C10	M{nJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRThwNEmgcm0>	MUfTRW5ITVJ?
MHH-PREB-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HSO2lEPTB;OT6xNkBvVQ>?	NFzCWoJUSU6JRWK=
DU-4475	M17Hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHXTWM2OD17LkS0JI5O	MVPTRW5ITVJ?
NCI-H1666	M2T3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzvd4tuUUN3ME25MlcyKG6P	M4TncHNCVkeHUh?=
CAMA-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvEbXFKSzVyPUmuPEBvVQ>?	M{LtWnNCVkeHUh?=
TYK-nu	M3P6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlmwTWM2OD17Lkm0JI5O	NV7MRVJqW0GQR1XS
MFE-280	NWrtSlJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TQWWlEPTB;OT65PUBvVQ>?	M3vJOHNCVkeHUh?=
A549	M2iyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHC[mRKSzVyPUGwMlE1KG6P	MWLTRW5ITVJ?
769-P	NGO2PZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTFyLkS0JI5O	MmTMV2FPT0WU
L-363	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTFyLk[5JI5O	Mk\hV2FPT0WU
ES8	NED0UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvrd3FKSzVyPUGwMlkhdk1?	MmDhV2FPT0WU
PA-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XYdGlEPTB;MUGuPFIhdk1?	Mn:3V2FPT0WU
Mewo	M3XUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\QNHlHUUN3ME2xNU46QSCwTR?=	MWLTRW5ITVJ?
HSC-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWmwbFFWUUN3ME2xNk4zOSCwTR?=	NFXwe2dUSU6JRWK=
H4	M4q2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXITWM2OD1zMj62O{BvVQ>?	MonoV2FPT0WU
BB65-RCC	NUXwe5pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYe4W3lYUUN3ME2xNk44OiCwTR?=	M3W1dnNCVkeHUh?=
NCI-H1793	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTF{LkiyJI5O	NWjUV2tCW0GQR1XS
KARPAS-45	NUPZPZhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTF\|LkWxJI5O	NED5botUSU6JRWK=
GCT	M3n4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmm4TWM2OD1zMz62PEBvVQ>?	M13UWHNCVkeHUh?=
EoL-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7VdHRqUUN3ME2xN{46OyCwTR?=	MknsV2FPT0WU
LB2241-RCC	M3u1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7q[5k5UUN3ME2xOE4xOSCwTR?=	MVvTRW5ITVJ?
ES5	M4nmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fCTGlEPTB;MUSuO\|Qhdk1?	MoTPV2FPT0WU
LOXIMVI	NGW5fnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlH0TWM2OD1zND65PUBvVQ>?	NV3kR\|R5W0GQR1XS
COR-L105	M1\xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDkU5NMUUN3ME2xOU4xPCCwTR?=	NX\zPZBHW0GQR1XS
P12-ICHIKAWA	M4nCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nERmlEPTB;MUWuNUBvVQ>?	NVv3b\|Z7W0GQR1XS
CHL-1	M37BbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X2UGlEPTB;MUWuOFUhdk1?	NHfoTohUSU6JRWK=
VMRC-RCZ	MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYW4d\|hsUUN3ME2xOU43OyCwTR?=	MnvGV2FPT0WU
HH	NIjUNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HyNWlEPTB;MUWuO{BvVQ>?	MW\TRW5ITVJ?
NUGC-3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLOTWM2OD1zNj6zOEBvVQ>?	M2CxfXNCVkeHUh?=
EGI-1	NVrCeXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjLZZRKSzVyPUG2MlQ{KG6P	MlHIV2FPT0WU
OS-RC-2	NV:xb5hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTF4LkS3JI5O	NXPMZXNbW0GQR1XS
MOLT-16	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfEXW9KSzVyPUG3MlE2KG6P	MnnYV2FPT0WU
NCI-H209	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\ud2xKSzVyPUG3MlI6KG6P	M4jDUXNCVkeHUh?=
697	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDGOlBKSzVyPUG3MlQ{KG6P	MoLHV2FPT0WU
D-56MG	MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHJV5dQUUN3ME2xO{43QSCwTR?=	MkC3V2FPT0WU
VA-ES-BJ	NHzZcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LmPWlEPTB;MUeuPFMhdk1?	M1rFXnNCVkeHUh?=
EW-16	NWPCdlJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHRdZdKSzVyPUG4MlA1KG6P	NF\UbINUSU6JRWK=
HGC-27	NF\mdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjXfWxGUUN3ME2xPE4xPiCwTR?=	MlzEV2FPT0WU
ES7	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTF6LkC5JI5O	M{TrVHNCVkeHUh?=
HuH-7	NGrPTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPF[oRKSzVyPUG4MlQhdk1?	M4DHc3NCVkeHUh?=
BCPAP	NVLqdlBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLVbId7UUN3ME2xPE43PSCwTR?=	NEDCb4ZUSU6JRWK=
SW1710	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fSSGlEPTB;MUiuO\|Ihdk1?	M2DnS3NCVkeHUh?=
IST-MEL1	NWrIVHVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvyeGZKSzVyPUG4Mlc4KG6P	Mmj3V2FPT0WU
SF295	NIK1SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DnS2lEPTB;MUiuPVMhdk1?	NFvwRYtUSU6JRWK=
RPMI-7951	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTF7LkK4JI5O	MVzTRW5ITVJ?
SF126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LZ[2lEPTB;MUmuOFEhdk1?	NW[yRlU1W0GQR1XS
GAMG	NHjt[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXoeVZKSzVyPUG5MlQ5KG6P	MkOzV2FPT0WU
KNS-81-FD	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTF7LkW0JI5O	NFjiSY9USU6JRWK=
RT-112	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDOe\|V2UUN3ME2xPU43PiCwTR?=	MYjTRW5ITVJ?
DEL	NULqTplJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzVbFltUUN3ME2yNE41QSCwTR?=	M1S1OnNCVkeHUh?=
CGTH-W-1	NXrlNoNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTDTGtIUUN3ME2yNE43OyCwTR?=	MYLTRW5ITVJ?
HOS	NVfYT2RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTJzLkC2JI5O	NGTtbZJUSU6JRWK=
ES4	NInnd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXvZYtiUUN3ME2yNU4xQCCwTR?=	NVPHSpprW0GQR1XS
RXF393	NGLifIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnWxTWM2OD1{MT60OUBvVQ>?	MkmyV2FPT0WU
NCI-H2030	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJzLkWyJI5O	MkfaV2FPT0WU
YH-13	M1GxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13SdWlEPTB;MkGuPFghdk1?	NGHrcpFUSU6JRWK=
HT-1080	NHHkSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3OTWM2OD1{MT65N{BvVQ>?	NVHuTHRVW0GQR1XS
NCI-SNU-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfR[nh7UUN3ME2yNU46PSCwTR?=	MVzTRW5ITVJ?
G-402	NV\ab2ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\rTWM2OD1{Mj6xOkBvVQ>?	NHzG[pBUSU6JRWK=
786-0	NHvuTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\hNmZTUUN3ME2yNk4zQSCwTR?=	MnLnV2FPT0WU
ME-180	NGn5bHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV[zdlRuUUN3ME2yNk41OyCwTR?=	M3K0cnNCVkeHUh?=
NB69	MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M331[GlEPTB;MkKuOVMhdk1?	Mlz2V2FPT0WU
J-RT3-T3-5	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVOwT5o{UUN3ME2yNk46PiCwTR?=	NF7adIdUSU6JRWK=
TGBC1TKB	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3VXYcyUUN3ME2yN{4xPSCwTR?=	MkHBV2FPT0WU
SW780	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXxZ29KSzVyPUKzMlE{KG6P	MXTTRW5ITVJ?
MG-63	M{\mRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkCxTWM2OD1{Mz60OUBvVQ>?	NVr5d2hDW0GQR1XS
BV-173	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnVTWM2OD1{Mz64O{BvVQ>?	NHfW[41USU6JRWK=
CAL-51	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUH1Sm1tUUN3ME2yN{45QSCwTR?=	NHrqcGNUSU6JRWK=
A375	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJ\|LkmzJI5O	M2CxSHNCVkeHUh?=
MEL-HO	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWC0bmJLUUN3ME2yOE4xPCCwTR?=	NH24coJUSU6JRWK=
EFO-27	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGqyN\|ZKSzVyPUK0MlM{KG6P	NVLESFRuW0GQR1XS
Hs-578-T	M4HpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHZTWM2OD1{ND61PEBvVQ>?	MV3TRW5ITVJ?
NBsusSR	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MluzTWM2OD1{ND62JI5O	M3fhfHNCVkeHUh?=
CTB-1	NHf5PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXniPJh4UUN3ME2yOE43PyCwTR?=	MX\TRW5ITVJ?
FTC-133	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTJ3LkGgcm0>	M4foTHNCVkeHUh?=
MOLT-4	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[2Vm1ZUUN3ME2yOU4yOiCwTR?=	MmTSV2FPT0WU
HO-1-N-1	NH[ye3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnmSnprUUN3ME2yOU4yPSCwTR?=	NUPqNpBYW0GQR1XS
ES3	M1jCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELYN5lKSzVyPUK1MlIzKG6P	M3nlPHNCVkeHUh?=
TI-73	M4nlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4C1cGlEPTB;MkWuNlghdk1?	M2XGRXNCVkeHUh?=
MPP-89	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rXNmlEPTB;MkWuN\|Ihdk1?	NGHmd\|JUSU6JRWK=
KYSE-150	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJ3Lki5JI5O	NFHwdIJUSU6JRWK=
LXF-289	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvYS5h3UUN3ME2yOk4xPCCwTR?=	MmjSV2FPT0WU
SK-LU-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3KTWM2OD1{Nj6xO{BvVQ>?	NX;FdHNzW0GQR1XS
HOP-92	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmH5TWM2OD1{Nj60PEBvVQ>?	MY\TRW5ITVJ?
HuO9	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkC2TWM2OD1{Nj63OkBvVQ>?	Mo\xV2FPT0WU
SW962	NYXINHloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJ4Lke2JI5O	NX7CcXdSW0GQR1XS
RS4-11	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7vUpVlUUN3ME2yOk46OSCwTR?=	MVHTRW5ITVJ?
NCI-H292	M2S0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O5WmlEPTB;Mkegcm0>	MkfHV2FPT0WU
DB	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17PbGlEPTB;MkeuN\|Yhdk1?	NFn2PY1USU6JRWK=
SW1088	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJ6LkK5JI5O	NXjueVZKW0GQR1XS
A204	M{D6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJ6LkS3JI5O	MYDTRW5ITVJ?
A3-KAW	M{\2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTJ6Lk[0JI5O	NHnUSotUSU6JRWK=
MV-4-11	M1LWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7LTWM2OD1{OD63JI5O	NHy1SllUSU6JRWK=
ES1	NWjpO49YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{G5SmlEPTB;MkiuPFQhdk1?	MXrTRW5ITVJ?
ONS-76	NF34T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fYSWlEPTB;MkmuNFUhdk1?	MlHHV2FPT0WU
D-263MG	NVXFUmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJ7LkO1JI5O	NGXmdXNUSU6JRWK=
U-2-OS	M3;oO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDqTWM2OD1{OT61JI5O	M1XHWnNCVkeHUh?=
T98G	M1fHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPXUplKSzVyPUK5Mlg5KG6P	MnPaV2FPT0WU
GI-ME-N	NWDTTVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPX[m5KSzVyPUK5MlkyKG6P	NHHFV4NUSU6JRWK=
BHT-101	NWHLZWJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnpZVJKSzVyPUOwMlA2KG6P	M4PRSXNCVkeHUh?=
NOS-1	M3nRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojJTWM2OD1\|MD6xNkBvVQ>?	M4nWNHNCVkeHUh?=
AsPC-1	M2C5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XTZ2lEPTB;M{CuNkBvVQ>?	NIGxW2JUSU6JRWK=
QIMR-WIL	M3THfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTNyLk[gcm0>	NV:zPWNuW0GQR1XS
JVM-3	M1\F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrmbINKSzVyPUOwMlg{KG6P	MX7TRW5ITVJ?
KU-19-19	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrCfGxKSzVyPUOxMlE{KG6P	NWTMdXhDW0GQR1XS
OVCAR-8	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVq3W5pHUUN3ME2zNU4zPiCwTR?=	MYHTRW5ITVJ?
BEN	MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\ZeFA3UUN3ME2zNU43OyCwTR?=	NELhbpVUSU6JRWK=
BE-13	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2X3UWlEPTB;M{GuPFIhdk1?	M{LaVXNCVkeHUh?=
EW-18	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXhfYhKSzVyPUOxMlg3KG6P	M1flZXNCVkeHUh?=
ECC10	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXv4e5ZQUUN3ME2zNU46PSCwTR?=	M2fMS3NCVkeHUh?=
CTV-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTN{LkiyJI5O	NHjXUYFUSU6JRWK=
COLO-800	M{XsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIqxN5ZKSzVyPUOyMlkzKG6P	MkHQV2FPT0WU
A2058	NGDOXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUe3bpM1UUN3ME2zN{4zPSCwTR?=	Mk\xV2FPT0WU
VM-CUB-1	NX;xfXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXr1W3A4UUN3ME2zN{41OyCwTR?=	Mmq5V2FPT0WU
Ca9-22	MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\kTWM2OD1\|Mz61OUBvVQ>?	MXvTRW5ITVJ?
COLO-684	NUPwWpZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zrWmlEPTB;M{OuOVghdk1?	M{DVVXNCVkeHUh?=
RPMI-8226	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLzfXdYUUN3ME2zN{45OiCwTR?=	M1zXVnNCVkeHUh?=
SK-NEP-1	M1\4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXW4PYJFUUN3ME2zOE4yPSCwTR?=	MonGV2FPT0WU
Becker	Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDjTWM2OD1\|ND6yNUBvVQ>?	M1jhc3NCVkeHUh?=
NCI-H28	NUTpRopOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIr4c4FKSzVyPUO0MlQ1KG6P	NYWzeZRyW0GQR1XS
CAL-120	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M36xOWlEPTB;M{SuO\|Ihdk1?	M{LrXXNCVkeHUh?=
MDA-MB-157	NEPqU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUD6R3BEUUN3ME2zOU41OSCwTR?=	MULTRW5ITVJ?
OVCAR-5	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjKd5pKSzVyPUO1MlQ4KG6P	MXXTRW5ITVJ?
LAMA-84	NXOwPGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rGUGlEPTB;M{WuPFchdk1?	NYG3XXFpW0GQR1XS
CAKI-1	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzTTWM2OD1\|Nj60N{BvVQ>?	MoTQV2FPT0WU
Daoy	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3K0dWlEPTB;M{[uO{BvVQ>?	M3PPUHNCVkeHUh?=
CAL-62	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTRdYtQUUN3ME2zOk45PiCwTR?=	MnjuV2FPT0WU
8-MG-BA	NGTWZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7JTWM2OD1\|Nz6yOUBvVQ>?	MVjTRW5ITVJ?
8505C	NI\KOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XvS2lEPTB;M{euOVEhdk1?	MlrjV2FPT0WU
LNCaP-Clone-FGC	NXvHVG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIO3S3dKSzVyPUO3MlU6KG6P	NHjuN4RUSU6JRWK=
CAL-39	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWKzdGhKUUN3ME2zO{46KG6P	MWDTRW5ITVJ?
MN-60	NXPBd4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7BN45KSzVyPUO3Mlk3KG6P	NWHMfpVsW0GQR1XS
RKO	NWH5NHRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTN6LkOzJI5O	NFGyO\|lUSU6JRWK=
U251	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;5fWlEPTB;M{iuOFMhdk1?	M2jjVXNCVkeHUh?=
SJSA-1	NH:0S3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN6LkW0JI5O	MorwV2FPT0WU
CAL-12T	NUfDbJl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnv0TWM2OD1\|OD62JI5O	M4X6PHNCVkeHUh?=
HCC1419	NXK4RmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rpemlEPTB;M{iuO\|Ehdk1?	MlfXV2FPT0WU
CO-314	NFTlTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTLRYpyUUN3ME2zPE44PCCwTR?=	NHvmeo9USU6JRWK=
LB1047-RCC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\yXXRKSzVyPUO4MlgyKG6P	NFTqeWJUSU6JRWK=
A101D	NXHydo1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXCTWM2OD1\|OD65O{BvVQ>?	M2W5ZXNCVkeHUh?=
MDA-MB-175-VII	M37LZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLrOJh4UUN3ME2zPU42OSCwTR?=	Mm\2V2FPT0WU
MZ2-MEL	M1TVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLMTWM2OD1\|OT62OkBvVQ>?	Ml;zV2FPT0WU
NB5	M{PQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEC5[IFKSzVyPUSwMlY1KG6P	NY\RXWFXW0GQR1XS
G-401	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHIT3NKSzVyPUSwMlgzKG6P	NHLsdpdUSU6JRWK=
HT	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MortTWM2OD12MT6wNkBvVQ>?	NXz6eHg5W0GQR1XS
8305C	M2DoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH64bXBKSzVyPUSxMlg4KG6P	M2r4cnNCVkeHUh?=
BHY	MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHyTWM2OD12Mj63NkBvVQ>?	NW\ld3pTW0GQR1XS
NTERA-S-cl-D1	M3nnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTBTWM2OD12MzDuUS=>	MV3TRW5ITVJ?
T-24	NU\ld2psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPWOIZKSzVyPUSzMlg{KG6P	NUTmbnB4W0GQR1XS
EPLC-272H	NWDYUVIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHZe\|dWUUN3ME20OE4{QSCwTR?=	NXPwWmU2W0GQR1XS
PSN1	NYfhdmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvrTWM2OD12ND60JI5O	MVnTRW5ITVJ?
NCI-H2452	M4jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPQTWM2OD12ND61PEBvVQ>?	NFHCUFRUSU6JRWK=
KS-1	NXLFbFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWCwTYU{UUN3ME20OE43PiCwTR?=	M{nZ[HNCVkeHUh?=
HD-MY-Z	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTR2LkmyJI5O	NUHRUXd1W0GQR1XS
KNS-62	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmO3TWM2OD12NT6zPEBvVQ>?	M2\LWnNCVkeHUh?=
NOMO-1	NUHtdZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjETXlqUUN3ME20OU45PyCwTR?=	NYPGR25wW0GQR1XS
SK-HEP-1	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{mwXGlEPTB;NE[uNFQhdk1?	Mlm2V2FPT0WU
IGR-1	NIK4T2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTR4LkGzJI5O	M1;obHNCVkeHUh?=
KYSE-180	M3\yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7FNFBKSzVyPUS2MlE4KG6P	NETY[mdUSU6JRWK=
EW-22	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHSyWo1KSzVyPUS2MlIhdk1?	NH3hcIRUSU6JRWK=
NCI-H1355	M{jUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljsTWM2OD12Nj6zOEBvVQ>?	MVHTRW5ITVJ?
DOHH-2	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\0TWM2OD12Nj6zO{BvVQ>?	MU\TRW5ITVJ?
A4-Fuk	NEDhZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLlTWM2OD12Nj61NkBvVQ>?	NYTMbVFuW0GQR1XS
PC-14	NVS5PJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTR4LkW3JI5O	M2j0XXNCVkeHUh?=
TE-5	NX[ySndzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTR4Lki0JI5O	NGK5VFlUSU6JRWK=
LB996-RCC	NWfTSpVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O2dWlEPTB;NEeuNVkhdk1?	MXjTRW5ITVJ?
NCI-H1623	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTR5Lke2JI5O	NV3aVnVpW0GQR1XS
NCI-H1155	NEjkU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFL6OItKSzVyPUS4MlMzKG6P	NUXXNYxMW0GQR1XS
LoVo	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTR6LkSgcm0>	NFLXUoZUSU6JRWK=
MCF7	NGfNd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\K[mZKSzVyPUS4MlU5KG6P	MXTTRW5ITVJ?
AGS	NGTLXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3u2SmlEPTB;NEiuO\|chdk1?	MkXjV2FPT0WU
PFSK-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTR7LkC2JI5O	M{fzNnNCVkeHUh?=
22RV1	NW\p[m5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzwWXNKSzVyPUS5MlA6KG6P	M1\sOXNCVkeHUh?=
COR-L23	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTOTWM2OD12OT6xOkBvVQ>?	NIq1RYhUSU6JRWK=
D-283MED	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLnPJVKSzVyPUS5MlYyKG6P	NVraWZRSW0GQR1XS
SW982	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\4PZBMUUN3ME20PU46OSCwTR?=	NFzOVpJUSU6JRWK=
SW620	MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTVyLkO2JI5O	MmPjV2FPT0WU
KYSE-140	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\PXpVKSzVyPUWwMlU2KG6P	M2i0bHNCVkeHUh?=
GCIY	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu1RoRKSzVyPUWwMlY4KG6P	MXPTRW5ITVJ?
MHH-ESS-1	M3KxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnDVHVKSzVyPUWxMlk2KG6P	NHzlUmhUSU6JRWK=
D-423MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnhTWM2OD13Mj6wPEBvVQ>?	MX3TRW5ITVJ?
SF539	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrXS4VKSzVyPUWyMlM2KG6P	M{\xc3NCVkeHUh?=
RPMI-2650	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3sRmpKSzVyPUWyMlY6KG6P	MnW4V2FPT0WU
GR-ST	NITz[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfWS\|l2UUN3ME21Nk45PyCwTR?=	MlfmV2FPT0WU
YKG-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvUTVdIUUN3ME21N{BvVQ>?	MU\TRW5ITVJ?
SK-MES-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTV\|LkK2JI5O	NYThRmJVW0GQR1XS
HLE	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\FTXFKSzVyPUWzMlQ4KG6P	M{DFSHNCVkeHUh?=
RVH-421	M{mzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ixS2lEPTB;NUOuOlchdk1?	M3TkRXNCVkeHUh?=
C32	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPvTXhKSzVyPUWzMlg{KG6P	NUPITYNTW0GQR1XS
GB-1	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTV2LkKgcm0>	NX;URVFGW0GQR1XS
SNB75	NV:2SFVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHOeJpoUUN3ME21OE4zPiCwTR?=	NX25boFYW0GQR1XS
EM-2	M4H4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\yTWM2OD13ND60JI5O	M1zCNnNCVkeHUh?=
RH-1	M3jSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L3bmlEPTB;NUSuO{BvVQ>?	MmPRV2FPT0WU
NKM-1	NFv6[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TBd2lEPTB;NUSuPFEhdk1?	NXHI[pc2W0GQR1XS
NCI-H2405	NITjb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX2TWM2OD13ND64PEBvVQ>?	MlPOV2FPT0WU
KYSE-450	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXaTWM2OD13NT6xOkBvVQ>?	M1zOSHNCVkeHUh?=
A704	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTV3LkW5JI5O	NW\FO4I{W0GQR1XS
HAL-01	NUnWXHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\5UWlEPTB;NUWuPFMhdk1?	M3:2OHNCVkeHUh?=
TE-11	NYGwN\|hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEf2W\|RKSzVyPUW1Mlk6KG6P	NH\1b21USU6JRWK=
DOK	NV7HSlh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHNU\|J4UUN3ME21Ok4xOiCwTR?=	Ml3pV2FPT0WU
KY821	NEL2ZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfVSGw4UUN3ME21Ok4zKG6P	MVjTRW5ITVJ?
KGN	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTV4LkOyJI5O	MVHTRW5ITVJ?
MC116	NEO5VWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLDTWM2OD13Nz64JI5O	MlywV2FPT0WU
PANC-08-13	M3r1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTV6LkCxJI5O	MWHTRW5ITVJ?
KE-37	NI\5N\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPmeW9xUUN3ME21PE44PyCwTR?=	MXjTRW5ITVJ?
KYSE-410	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\kOIo2UUN3ME21PU41PyCwTR?=	NXTzUXVwW0GQR1XS
RO82-W-1	M{j1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfWTWM2OD13OT65JI5O	M4Tr[nNCVkeHUh?=
M14	NVW1[XhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTZyLkC0JI5O	NHjCd25USU6JRWK=
GI-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTZyLkOgcm0>	M2LocXNCVkeHUh?=
ML-2	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fhSWlEPTB;NkCuOlIhdk1?	NW\xbYs5W0GQR1XS
BFTC-905	NVS1OJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXiZpdKSzVyPU[wMlY2KG6P	NHnPPVhUSU6JRWK=
DMS-273	NXmxOZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHP6R4lKSzVyPU[wMlg4KG6P	M2rDN3NCVkeHUh?=
MDA-MB-361	NWXlR5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknHTWM2OD14MTDuUS=>	M4Tue3NCVkeHUh?=
MSTO-211H	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTCNVVwUUN3ME22N{42OSCwTR?=	MnrDV2FPT0WU
MEG-01	NGXicIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfGdpRmUUN3ME22N{42OiCwTR?=	MUjTRW5ITVJ?
M059J	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTZ\|LkW4JI5O	MoD2V2FPT0WU
LN-405	NXfVS\|VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTZ\|Lki1JI5O	Mn;wV2FPT0WU
NCI-H1581	M4HG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTZ2LkCzJI5O	MnLyV2FPT0WU
TCCSUP	NVnRdZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljUTWM2OD14ND61N{BvVQ>?	Moi1V2FPT0WU
SW872	Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLQRVJSUUN3ME22OE42PyCwTR?=	NXvVc3JzW0GQR1XS
KYSE-510	NHG4Nm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\GTm1KSzVyPU[1Mlc2KG6P	MV7TRW5ITVJ?
NCI-H1792	M1nWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{W1SWlEPTB;Nk[uNVUhdk1?	MVPTRW5ITVJ?
SW13	NGnH[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33YUWlEPTB;Nk[uOUBvVQ>?	MoLMV2FPT0WU
TE-8	NHvlS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTZ4LkWyJI5O	Mnj4V2FPT0WU
SCH	NEDGWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ixbmlEPTB;NkeuNUBvVQ>?	MXnTRW5ITVJ?
NEC8	M2flN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPxSlBoUUN3ME22O{4zPCCwTR?=	M1n5cXNCVkeHUh?=
HuO-3N1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzpOmFKSzVyPU[3MlMyKG6P	NX;sOYJDW0GQR1XS
EFM-19	NFTBPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn6xTWM2OD14Nz61JI5O	NGnuendUSU6JRWK=
HEC-1	M{fsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3PWGNKSzVyPU[3MlUzKG6P	MoX4V2FPT0WU
T47D	NX7XfVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTZ5Lki3JI5O	MV7TRW5ITVJ?
SNU-423	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTZ5Lkm4JI5O	MknxV2FPT0WU
WM-115	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HjSmlEPTB;NkiuNVQhdk1?	NX:1NoY2W0GQR1XS
CaR-1	M1;UeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULtbndYUUN3ME22PE4zPSCwTR?=	M{HHZXNCVkeHUh?=
KU812	NXHuXZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILRNmhKSzVyPU[4MlY6KG6P	NYjmTVN1W0GQR1XS
AM-38	M{GySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTZ7LkOxJI5O	NUmyc5NVW0GQR1XS
KOSC-2	M2\Remdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTZ7Lkm3JI5O	MlXPV2FPT0WU
MC-IXC	NWG5RVZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvpTWM2OD15MD6wPEBvVQ>?	M{jTcnNCVkeHUh?=
SCC-4	NVrT[lBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\pfWlEPTB;N{GuN\|ghdk1?	NXv4bppyW0GQR1XS
Calu-3	NVraeGNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVu0NJd{UUN3ME23NU46QCCwTR?=	NX3keY1xW0GQR1XS
RPMI-8866	Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTd{LkiyJI5O	MYDTRW5ITVJ?
OVCAR-4	M2fXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLje3hKSzVyPUezMlM3KG6P	NHjxb4pUSU6JRWK=
OAW-42	M3;NNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2f4V2lEPTB;N{OuN\|khdk1?	NE\tdYRUSU6JRWK=
ATN-1	NUOxZ5UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\ObmJ4UUN3ME23N{45PyCwTR?=	NESyOphUSU6JRWK=
CHP-212	NGK5WJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTaTWM2OD15ND65OUBvVQ>?	M1HLTXNCVkeHUh?=
C2BBe1	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfMOnRQUUN3ME23OU4xOyCwTR?=	M3r2dnNCVkeHUh?=
A498	M1vyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjmWnpuUUN3ME23OU4yPSCwTR?=	MYHTRW5ITVJ?
SH-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnWWoJKSzVyPUe1MlIyKG6P	NYXRVXRSW0GQR1XS
SNU-449	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7KTWM2OD15NT63PUBvVQ>?	Ml;pV2FPT0WU
RD	NVnLcYVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3noc2lEPTB;N{WuPFYhdk1?	MnnQV2FPT0WU
PANC-03-27	NVLVXWVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XDTGlEPTB;N{[uNlUhdk1?	NEf4SGZUSU6JRWK=
S-117	NEDRUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrHcFQzUUN3ME23Ok4zPyCwTR?=	NHr2cnhUSU6JRWK=
SK-MEL-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvUOIpKSzVyPUe2Mlc2KG6P	MUHTRW5ITVJ?
LK-2	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPrTWM2OD15Nz6wOUBvVQ>?	NHrNZYpUSU6JRWK=
CP50-MEL-B	MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXKcW85UUN3ME23O{41KG6P	MnnPV2FPT0WU
647-V	M2jNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XmdGlEPTB;N{iuNFchdk1?	NVq0VGlKW0GQR1XS
LU-134-A	NUnwTWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWj6foNuUUN3ME23PU4xOyCwTR?=	NWLWOmpFW0GQR1XS
5637	NX7jZY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHzNWZXUUN3ME23PU4zOyCwTR?=	MnqyV2FPT0WU
NCI-H1437	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LqWmlEPTB;OECuOUBvVQ>?	M4roc3NCVkeHUh?=
NCI-H460	M4iyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjHcIpKSzVyPUixMlI{KG6P	Mn2xV2FPT0WU
BxPC-3	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHJN2NKSzVyPUixMlQ3KG6P	Mn2yV2FPT0WU
CAN	NYq2c\|BZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPqTWM2OD16MT64OEBvVQ>?	NX;Ic4sxW0GQR1XS
KINGS-1	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTjTWM2OD16Mj6zNkBvVQ>?	NFf1NGFUSU6JRWK=
OCUB-M	NIHaXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X3NmlEPTB;OEKuOFEhdk1?	MkPPV2FPT0WU
KALS-1	NEO5fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX[3bXlPUUN3ME24Nk42PCCwTR?=	Mn7JV2FPT0WU
OCI-AML2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LkNWlEPTB;OEKuOlEhdk1?	NE\oR5FUSU6JRWK=
A253	NFrj[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\ZOmhKSzVyPUiyMlY2KG6P	MVrTRW5ITVJ?
LCLC-97TM1	NFi5ZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jCTmlEPTB;OEKuPFYhdk1?	NIi5RZJUSU6JRWK=
NCI-H520	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHj3cFNKSzVyPUizMlA3KG6P	MXvTRW5ITVJ?
P30-OHK	M3nMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTh\|LkWgcm0>	MlXRV2FPT0WU
SBC-5	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGW2T3RKSzVyPUizMlUzKG6P	MYDTRW5ITVJ?
HCE-T	NFvJ[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTh\|Lke0JI5O	MVTTRW5ITVJ?
JEG-3	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofxTWM2OD16ND6xJI5O	MUPTRW5ITVJ?
KG-1	NWfzbnJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLPVHBnUUN3ME24OE4zPCCwTR?=	MYTTRW5ITVJ?
MIA-PaCa-2	M4PO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3WxdWlEPTB;OESuOVQhdk1?	MkTaV2FPT0WU
CAL-33	NWexVGJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHscnhTUUN3ME24OU4xQCCwTR?=	MXPTRW5ITVJ?
639-V	NYfGUYdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTNbJZKSzVyPUi1MlQzKG6P	M3T3fnNCVkeHUh?=
NCI-H1048	NWW1cFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LVZmlEPTB;OE[uN\|Ehdk1?	NYS1[JZlW0GQR1XS
NCI-H1573	NHKzT\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIW0WHpKSzVyPUi3MlQ5KG6P	NILjcnZUSU6JRWK=
NCI-H2228	NUTrPYZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7uNWdKSzVyPUi4MlI3KG6P	M2HCcHNCVkeHUh?=
NB14	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIiwT3lKSzVyPUi4MlMhdk1?	MnfTV2FPT0WU
SCC-25	NVTseVhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTh7LkiyJI5O	NIixXndUSU6JRWK=
A431	M1zrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\Ob2V3UUN3ME24PU46PyCwTR?=	NHLBUoVUSU6JRWK=
SN12C	NVTo[oxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGj1ZYZKSzVyPUmwMlYzKG6P	MnrhV2FPT0WU
HuCCT1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTlyLke2JI5O	M{XwTHNCVkeHUh?=
LS-123	NYno[XVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzCTWM2OD17Mj6xPEBvVQ>?	M{DP[HNCVkeHUh?=
CAL-85-1	M13Fbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPLWmpYUUN3ME25Nk41QCCwTR?=	NHLuZ3pUSU6JRWK=
ES6	NI\CfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDXTWM2OD17Mj64N{BvVQ>?	NGDEdnZUSU6JRWK=
NCI-H650	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjac3lKSzVyPUm0MlA6KG6P	MkTJV2FPT0WU
NCI-H446	NH3YbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFriSIpKSzVyPUm1MlEzKG6P	NEHOV3pUSU6JRWK=
EW-13	M1vNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\kNWtMUUN3ME25OU44PSCwTR?=	MX7TRW5ITVJ?
HSC-2	MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3K5T2lEPTB;OUWuPFkhdk1?	M3vTWnNCVkeHUh?=
U031	M171Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PQWGlEPTB;OU[uO\|Mhdk1?	NEfOWmtUSU6JRWK=
EW-11	NHfBOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHnRmxHUUN3ME25Ok45QCCwTR?=	MlP6V2FPT0WU
GAK	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDjTWM2OD17OD65N{BvVQ>?	MX;TRW5ITVJ?
SK-OV-3	M1n6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:4ZY91UUN3ME2xNFAvODdibl2=	MlfPV2FPT0WU
OMC-1	M3P6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTFyMD6xPEBvVQ>?	NILFWIdUSU6JRWK=
TK10	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETNU2xKSzVyPUGwNE4zOSCwTR?=	NVPGU4tRW0GQR1XS
EKVX	NFrOcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTFyMD62JI5O	MVzTRW5ITVJ?
Detroit562	NUXscG9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXIXm5KSzVyPUGwNk4yPyCwTR?=	Mo\FV2FPT0WU
SF268	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFyMj6zOEBvVQ>?	NXTaN5FvW0GQR1XS
SNU-387	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLSTWM2OD1zMESuNVchdk1?	MUfTRW5ITVJ?
MDA-MB-231	NF\T[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPZSlZKSzVyPUGwOU4xPiCwTR?=	NIq2bVdUSU6JRWK=
NCI-H1563	M2WxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MliwTWM2OD1zMEWuNVghdk1?	NVrMTnNpW0GQR1XS
D-502MG	M4W5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXiVVNKSzVyPUGwOU44KG6P	M17BU3NCVkeHUh?=
A2780	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HWPWlEPTB;MUC2MlQ4KG6P	M4TpO3NCVkeHUh?=
IA-LM	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHQTWM2OD1zMEeuOVEhdk1?	M2ToeXNCVkeHUh?=
D-392MG	NUnqbHdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLpTWM2OD1zMEeuOVQhdk1?	NYnZWZVrW0GQR1XS
MS-1	M1HtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz1TWM2OD1zMEeuO\|Ehdk1?	MkLkV2FPT0WU
SW1990	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHEXpdKSzVyPUGwPE42PCCwTR?=	NIn6bYhUSU6JRWK=
HEL	NXe3TYZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;yN3dKSzVyPUGwPU4zQSCwTR?=	NHTBToFUSU6JRWK=
SW1573	NVS4RpVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVS1W2RrUUN3ME2xNFkvOzFibl2=	NH\WUmhUSU6JRWK=
SW1783	M4rJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;rWWlEPTB;MUGwMlIzKG6P	M2rUcXNCVkeHUh?=
COLO-680N	NELYNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTFzMD63OkBvVQ>?	MXnTRW5ITVJ?
NCI-N87	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFzMT6wOEBvVQ>?	NV;1fZdoW0GQR1XS
SK-MEL-28	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTFzMT61OUBvVQ>?	MoPXV2FPT0WU
BT-20	NH3XenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\ZfHdKSzVyPUGxNk4xOSCwTR?=	MmTPV2FPT0WU
NCI-H1648	NVXPe2t6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrkUHYyUUN3ME2xNVMhdk1?	NHPYbVlUSU6JRWK=
no-11	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fubWlEPTB;MUGzMlI5KG6P	NHjCcmNUSU6JRWK=
MOLT-13	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\rTWM2OD1zMUOuOFQhdk1?	MmqzV2FPT0WU
NCI-H2170	NX;1U5FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnEcYtKSzVyPUGxOE42OSCwTR?=	MojDV2FPT0WU
HTC-C3	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDzTnYzUUN3ME2xNVYvQDVibl2=	NFHYb5lUSU6JRWK=
LU-99A	M2f0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3SUVRRUUN3ME2xNVcvOjFibl2=	NIjifYtUSU6JRWK=
HCC2998	NEHR[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HCZWlEPTB;MUG3MlkzKG6P	NVfWU2lWW0GQR1XS
NB13	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIH2Z4FKSzVyPUGxO{46QSCwTR?=	NGLmUFRUSU6JRWK=
GT3TKB	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHO4UFNKSzVyPUGxPE4xQCCwTR?=	MmDUV2FPT0WU
BT-549	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ryUWlEPTB;MUG4Mlk2KG6P	MVTTRW5ITVJ?
NCI-H747	MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEi1cVNKSzVyPUGxPU4{PCCwTR?=	MVTTRW5ITVJ?
EW-1	M1noPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoCzTWM2OD1zMkCuNkBvVQ>?	M1rWOHNCVkeHUh?=
LB831-BLC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PwSWlEPTB;MUKwMlY{KG6P	NFmybJNUSU6JRWK=
NMC-G1	M2P6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17mWGlEPTB;MUKxMlEyKG6P	MYDTRW5ITVJ?
COLO-679	M1Ppc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILIU3lKSzVyPUGyNk4yPSCwTR?=	M3PUNHNCVkeHUh?=
HL-60	NWDCXXlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHKR5dKSzVyPUGyN{4yKG6P	NHXuW3VUSU6JRWK=
MKN7	NUDP[ox4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7DW\|kxUUN3ME2xNlMvQDNibl2=	M1HzZXNCVkeHUh?=
RERF-LC-MS	NHjTOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETVZZBKSzVyPUGyOE4{OSCwTR?=	MlzOV2FPT0WU
DMS-114	M2TJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\hNVA4UUN3ME2xNlUvODlibl2=	NHy4SFRUSU6JRWK=
HuP-T4	M1PUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LCU2lEPTB;MUK2Mlk4KG6P	M4HXU3NCVkeHUh?=
HCC2157	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTF{Nz61JI5O	M{Dr[nNCVkeHUh?=
SKG-IIIa	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\RV2lEPTB;MUK4Mlghdk1?	NG\INJlUSU6JRWK=
HCT-116	NH7LUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFW0dVFKSzVyPUGzNE43PCCwTR?=	MWnTRW5ITVJ?
BB30-HNC	M3Wzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHZNnVKSzVyPUGzNE44QCCwTR?=	MVTTRW5ITVJ?
KYSE-270	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXhTlVwUUN3ME2xN\|AvQDhibl2=	M4TpTXNCVkeHUh?=
MFM-223	NV3tOZBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLtZo1KSzVyPUGzNU42OSCwTR?=	MUHTRW5ITVJ?
NH-12	M1HtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPQfFJnUUN3ME2xN\|IvQTlibl2=	M{\6XHNCVkeHUh?=
U-118-MG	NHPkOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXzTWM2OD1zM{OuOlIhdk1?	NXf0TFFOW0GQR1XS
ESS-1	NIPqRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;oNoFoUUN3ME2xN\|UvOThibl2=	MVTTRW5ITVJ?
D-247MG	NYTYOHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzYW3N3UUN3ME2xN\|UvOjFibl2=	NF\TS2ZUSU6JRWK=
IGROV-1	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTF\|NT63OkBvVQ>?	MlrtV2FPT0WU
C-33-A	MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17BOWlEPTB;MUO1Mlk4KG6P	MmW2V2FPT0WU
NCI-H1693	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LjTGlEPTB;MUO2MlEzKG6P	MWTTRW5ITVJ?
MLMA	M4nhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkP1TWM2OD1zM{[uOVghdk1?	NHHuV5NUSU6JRWK=
SK-N-AS	NILQ[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF\|Nz6xO{BvVQ>?	M{jPUXNCVkeHUh?=
NCI-H1755	Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTF\|OD64OUBvVQ>?	NGPOSYtUSU6JRWK=
CHP-134	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXuPHVsUUN3ME2xN\|kvPTVibl2=	M2q1dHNCVkeHUh?=
LS-513	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\VVmlEPTB;MUSwMlkyKHCP	MlzwV2FPT0WU
TE-12	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIT4fpVKSzVyPUG0NE46OyCwTR?=	M1LVfHNCVkeHUh?=
KNS-42	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHWXnpsUUN3ME2xOFQvOyCwTR?=	MWfTRW5ITVJ?
SJRH30	NIrqS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\LTWM2OD1zNESuOFQhdk1?	NXPsXJpRW0GQR1XS
NCI-H1092	NHLKVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXle3prUUN3ME2xOFQvPTJibl2=	M1XQcnNCVkeHUh?=
H-EMC-SS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfjTWM2OD1zNE[uPFEhdk1?	NID3WnRUSU6JRWK=
SK-MEL-3	Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\0XmlEPTB;MUS3MlU2KG6P	MUXTRW5ITVJ?
SK-N-FI	NUWwdYFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jRSWlEPTB;MUS3MlU6KG6P	NX7BZYVYW0GQR1XS
NCI-H2126	NXfsT3liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDqfnZ2UUN3ME2xOFgvOTVibl2=	NXvT[pRWW0GQR1XS
NCI-H1299	NHHjfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXTelhKSzVyPUG1NE4zOiCwTR?=	M4TjcnNCVkeHUh?=
CFPAC-1	NInG[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PpVmlEPTB;MUWwMlY3KG6P	NITn[opUSU6JRWK=
NCI-H661	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzKZ41KSzVyPUG1NU4zPiCwTR?=	NHTZW4lUSU6JRWK=
KYSE-70	NF;LNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTF3MT63PUBvVQ>?	NGjn[3RUSU6JRWK=
SW900	NXrFeVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTF3ND62OUBvVQ>?	Mn7qV2FPT0WU
Ca-Ski	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjlbIlKSzVyPUG1Ok4{QSCwTR?=	NW\rTpBkW0GQR1XS
HPAF-II	NX;ZWFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXIeXl4UUN3ME2xOVYvPDdibl2=	M1jkdnNCVkeHUh?=
LB2518-MEL	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHYTWM2OD1zNUeuNUBvVQ>?	Mk\rV2FPT0WU
LC-2-ad	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjITWM2OD1zNUiuOlIhdk1?	MX3TRW5ITVJ?
HCC1806	NFzPe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HoU2lEPTB;MU[3Mlg5KG6P	NFW0[5hUSU6JRWK=
UACC-62	NGrWV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;ZVYVqUUN3ME2xOlgvODlibl2=	MWjTRW5ITVJ?
KM-H2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF5MD61PEBvVQ>?	NYXrdY5sW0GQR1XS
NCI-H2347	M{\sOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3kcVhiUUN3ME2xO\|IvPzJibl2=	MVzTRW5ITVJ?
SCC-15	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF5Mz62OkBvVQ>?	MXPTRW5ITVJ?
BB49-HNC	NF:0UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3KTWM2OD1zN{OuPFEhdk1?	MlvJV2FPT0WU
GMS-10	NIf6PYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fqdGlEPTB;MUezMlk1KG6P	MWLTRW5ITVJ?
NCI-H2052	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTF5ND65JI5O	M4e3NXNCVkeHUh?=
SW626	NFjyZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljJTWM2OD1zN{[uNFYhdk1?	M3rBS3NCVkeHUh?=
MDA-MB-415	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4i4ZWlEPTB;MUe2MlYyKG6P	MkDlV2FPT0WU
Saos-2	NXLPV5BbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1X1O2lEPTB;MUe5MlM2KG6P	NFO0VYNUSU6JRWK=
DK-MG	NUjNUGc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzHXJNKSzVyPUG4NE4{KG6P	MYHTRW5ITVJ?
SNU-C2B	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXw[\|VSUUN3ME2xPFAvPzNibl2=	MkK4V2FPT0WU
A427	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUi2W\|hDUUN3ME2xPFIvPTdibl2=	M2PkenNCVkeHUh?=
KP-N-YS	NYL5OZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLkdo5KSzVyPUG4OUBvVQ>?	M3fZXHNCVkeHUh?=
J82	MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEi0ZohKSzVyPUG4OU4yQCCwTR?=	NXfnNlJsW0GQR1XS
LS-411N	NI\KOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHWTWM2OD1zOEeuNlghdk1?	NWrRTmlHW0GQR1XS
HCC1937	M2DmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33HPWlEPTB;MUi3MlQ6KG6P	NUS0N3g2W0GQR1XS
OE33	M2\mVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrmbllSUUN3ME2xPFgvQTdibl2=	NXjLWGtzW0GQR1XS
NB7	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLzSHFKSzVyPUG4PU45QSCwTR?=	MYPTRW5ITVJ?
SW684	NUSxPIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vqbmlEPTB;MUm2MlE{KG6P	Mn\MV2FPT0WU
HT-144	M2jHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\YW29vUUN3ME2xPVYvOTVibl2=	NVj2c5ZbW0GQR1XS
SK-MEL-30	M1LScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGK4V21KSzVyPUG5Ok4zKG6P	M1PueXNCVkeHUh?=
DBTRG-05MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTF7OD60O{BvVQ>?	MXrTRW5ITVJ?
NCI-H1395	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjqSpFKSzVyPUG5PE45PSCwTR?=	MV;TRW5ITVJ?
NCI-H2122	M{O4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGe4TXpKSzVyPUKwNE42QSCwTR?=	NGKzVJVUSU6JRWK=
no-10	NV7QVVBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf2TWM2OD1{MEGuNFQhdk1?	NHvwfVdUSU6JRWK=
SW48	NEXEOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFj0R4RKSzVyPUKwNU4{OSCwTR?=	NVe1bndkW0GQR1XS
NCI-H1650	NEjZSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIL1dVFKSzVyPUKwOE4xOSCwTR?=	MkDHV2FPT0WU
MZ1-PC	NELVcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJyNT61PEBvVQ>?	NGTRNXBUSU6JRWK=
U-266	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDlTWM2OD1{MEWuO\|khdk1?	NWXLVYFwW0GQR1XS
CAS-1	M1HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2O5VmlEPTB;MkC3MlQ1KG6P	NFTk[2hUSU6JRWK=
AU565	M3HUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUj4e2poUUN3ME2yNVIvQDJibl2=	MnrHV2FPT0WU
UACC-257	M{HucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELlPZZKSzVyPUKxN{46QSCwTR?=	MlPFV2FPT0WU
CAL-27	MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3H3VGlEPTB;MkG3MlA2KG6P	NVjBbVZjW0GQR1XS
NCI-H23	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nON2lEPTB;MkG5MlM{KG6P	MnfBV2FPT0WU
TE-6	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVG3W2lSUUN3ME2yNVkvPjhibl2=	NUG2OlhlW0GQR1XS
TGBC24TKB	M2qwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ{Mj6xO{BvVQ>?	M3jTeHNCVkeHUh?=
TE-1	NXHLSoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nJe2lEPTB;MkKyMlg5KG6P	MV;TRW5ITVJ?
RCC10RGB	NHrDZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJ{ND6xPUBvVQ>?	NXL4WoF4W0GQR1XS
NCI-H596	NHPzW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJ{OD6yNkBvVQ>?	MnmwV2FPT0WU
SW954	NUHGT\|FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJ\|Mz64N{BvVQ>?	MUDTRW5ITVJ?
NCI-H2087	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTJ\|ND61NUBvVQ>?	NVrJNZBHW0GQR1XS
SK-PN-DW	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJ\|NT6xPUBvVQ>?	Mo\0V2FPT0WU
KM12	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS2PXVnUUN3ME2yN\|UvPyCwTR?=	NUnHNJNjW0GQR1XS
BT-474	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PiW2lEPTB;MkO1Mlc{KG6P	M1nZcHNCVkeHUh?=
IST-MES1	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfEfmdKSzVyPUKzOk42PyCwTR?=	MX3TRW5ITVJ?
HT-1197	NIfhfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJ\|OD6wPUBvVQ>?	M{\mdXNCVkeHUh?=
CAL-54	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3r4SGlEPTB;MkO4MlQ6KG6P	MVjTRW5ITVJ?
NB10	M13KWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjKVWhKSzVyPUK0NE4xPiCwTR?=	M1zHOnNCVkeHUh?=
PANC-10-05	NIjyRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPJTWM2OD1{NEWuOVYhdk1?	NFzYVpRUSU6JRWK=
NCI-H522	NIC0T4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTJ2OD6zNUBvVQ>?	Mk\ZV2FPT0WU
A388	NGf6UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULqS4J{UUN3ME2yOFkvQDJibl2=	NXu1[mNtW0GQR1XS
GOTO	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzadm1KSzVyPUK1NE4zQSCwTR?=	NFG2O\|FUSU6JRWK=
KLE	M1[wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7qTWM2OD1{NUGuPFchdk1?	M3rtNXNCVkeHUh?=
KYSE-520	M4P4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTJ3Mj64OkBvVQ>?	NFXBdZdUSU6JRWK=
HCE-4	MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rWSGlEPTB;Mk[yMlUhdk1?	NGjlc3lUSU6JRWK=
KURAMOCHI	NF\XdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIq4OJZKSzVyPUK2OU46KG6P	M2q0enNCVkeHUh?=
HCC38	MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTJ4Nj60PEBvVQ>?	MmHPV2FPT0WU
FADU	MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFO1bVRKSzVyPUK2Ok43OyCwTR?=	NIXxemtUSU6JRWK=
CW-2	NUSzUlI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjNTWM2OD1{NkmuPVYhdk1?	M4e2eHNCVkeHUh?=
L-428	M1\FXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37wcmlEPTB;Mke1MlE2KG6P	NFWzdopUSU6JRWK=
HCC1569	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfrTWM2OD1{N{WuPFQhdk1?	M1\UdXNCVkeHUh?=
NCI-H810	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJ5OD6zNUBvVQ>?	NVfkS3l7W0GQR1XS
LB771-HNC	M1zk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXkOGJKSzVyPUK4OU45PCCwTR?=	NGDkSpVUSU6JRWK=
LCLC-103H	NV63[WNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fpOmlEPTB;Mki1Mlk6KG6P	NIPEUm9USU6JRWK=
EFO-21	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPtTWM2OD1{OEeuOlghdk1?	NYXOUHhbW0GQR1XS
CAL-72	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnafGtbUUN3ME2yPVMvOTlibl2=	NIXvZpVUSU6JRWK=
SCC-9	NVr0R\|FWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJ7Mz6yNkBvVQ>?	MWHTRW5ITVJ?
COLO-829	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XKNGlEPTB;Mkm2MlUhdk1?	MYrTRW5ITVJ?
U-87-MG	NWfMNWpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzDS2p6UUN3ME2zNFAvPzNibl2=	NILYfGFUSU6JRWK=
MZ7-mel	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnO1TWM2OD1\|MkOuO\|Yhdk1?	M2LSUnNCVkeHUh?=
NCI-H1770	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3q3SWlEPTB;M{K2Mlc1KG6P	NGD1W3pUSU6JRWK=
ChaGo-K-1	M2\jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTN{OD6xJI5O	NGjRfGNUSU6JRWK=
SiHa	NX;mdWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHuz[FhKSzVyPUOyPU4zPCCwTR?=	MYXTRW5ITVJ?
NCI-SNU-5	NFTJcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnOTWM2OD1\|M{[uO\|chdk1?	MVrTRW5ITVJ?
DJM-1	NXnn[JM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3VUG5KSzVyPUO0NE4{OyCwTR?=	NHLhOY1USU6JRWK=
OE19	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTN2MD61N{BvVQ>?	NFX6W2hUSU6JRWK=
NCI-H1651	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTN2ND6xPEBvVQ>?	NH\t[mRUSU6JRWK=
COLO-792	NU\tcmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTN3ND60NkBvVQ>?	M1G5WXNCVkeHUh?=
ACHN	NXPIcmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXTeI5KSzVyPUO1Ok44OSCwTR?=	NWjTbGdpW0GQR1XS
TH-3	M1:5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDGTWM2OD1\|N{muPVUhdk1?	NX:0eIpLW0GQR1XS
HT-1376	M3;J[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXkTWM2OD1\|OESuPFghdk1?	NXixTHlZW0GQR1XS
RH-18	NFHPOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:1XVVKSzVyPUO5OE44PCCwTR?=	M1TFNHNCVkeHUh?=
NB6	M{TKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTN7Nj62OkBvVQ>?	NHjrRY1USU6JRWK=
COLO-320-HSR	NGTTXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTRyMz6zO{BvVQ>?	MYTTRW5ITVJ?
UACC-893	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnEblA1UUN3ME20NFYvPDdibl2=	MXXTRW5ITVJ?
DSH1	NUPuTIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XOR2lEPTB;NEC2MlkyKG6P	MmHZV2FPT0WU
TE-10	M4Hhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUKxVW55UUN3ME20NFcvODFibl2=	NIfHd4lUSU6JRWK=
HCC70	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTDTWM2OD12MEmuNlEhdk1?	NXf0S5pMW0GQR1XS
TGBC11TKB	NF7pcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVT1OHpjUUN3ME20NVAvOzNibl2=	NYX3d\|VKW0GQR1XS
NCI-H727	NHPnNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTRzMj6xNUBvVQ>?	NGLscmJUSU6JRWK=
ALL-PO	NIOwcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTRzNT62PUBvVQ>?	NVy1U4M1W0GQR1XS
ABC-1	NXvr[45{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPNTWM2OD12MkCuOFUhdk1?	MYLTRW5ITVJ?
NCI-H69	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2X2NGlEPTB;NEK2Mlc3KG6P	NXzydFlYW0GQR1XS
GP5d	NGD2fFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLHR29UUUN3ME20N\|QvPDFibl2=	NXPmfGppW0GQR1XS
UMC-11	M2DUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTR3OD6zOkBvVQ>?	MoDiV2FPT0WU
RMG-I	NVvFc2ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTR4Nz61OkBvVQ>?	NXP3fXliW0GQR1XS
YAPC	NWTJdIVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFntW3hKSzVyPUS5NE43KG6P	NEX4ZXRUSU6JRWK=
LS-1034	M1rwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHGwWlBKSzVyPUS5NU4xPiCwTR?=	NFTUZmRUSU6JRWK=
RCM-1	MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTOUphxUUN3ME20PVYvPjhibl2=	MlPwV2FPT0WU
HCC1954	NGTRU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInBSlVKSzVyPUWxNk42KG6P	NEHDS5NUSU6JRWK=
SK-MEL-24	NVTOSmZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTVzNj61NUBvVQ>?	M3;xeXNCVkeHUh?=
NB12	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTV{OD60NkBvVQ>?	MYTTRW5ITVJ?
SW756	M1fRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnIc3lKSzVyPUW1OE46PiCwTR?=	MkPDV2FPT0WU
HCC1187	M{XC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvUW4FKSzVyPUW3OU45OyCwTR?=	NWXpbG5OW0GQR1XS
NCI-H2342	NXjKc4VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTV7MD6zPUBvVQ>?	MWHTRW5ITVJ?
NCI-H2291	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPjbXZKSzVyPUW5PE4{OSCwTR?=	NFTQWGFUSU6JRWK=
OVCAR-3	M4\zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTJTWM2OD13OUiuPVYhdk1?	MoHuV2FPT0WU
MHH-NB-11	NWHNRphHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTZ{OT6wNUBvVQ>?	M3mzR3NCVkeHUh?=
SAS	M2HnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDMOZN5UUN3ME22OVIvPjdibl2=	NVy4S4lmW0GQR1XS
COLO-824	NXHnfZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\lR4U5UUN3ME22PFkvOzdibl2=	NYPxZW1JW0GQR1XS
HCC1395	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\0eGlEPTB;Nkm4MlUhdk1?	NWHVcZAzW0GQR1XS
COLO-668	M1q0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXkXGxKSzVyPUewOk4yKG6P	M17Se3NCVkeHUh?=
NCI-H226	M4jFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfNcFVKSzVyPUewO{45KG6P	MVTTRW5ITVJ?
NB17	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjNSmREUUN3ME23NlEvPzVibl2=	MoTjV2FPT0WU
SW1463	NGXvT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTd\|OT6xPUBvVQ>?	MnfSV2FPT0WU
TGW	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PDU2lEPTB;N{[wMlE2KG6P	NUnzNJhmW0GQR1XS
NCI-H526	M{ewT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTh{Mz61N{BvVQ>?	NIHYe5JUSU6JRWK=
COR-L88	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3ITI1qUUN3ME24OFgvOTJibl2=	M1jXWHNCVkeHUh?=
NCI-H441	NHTjUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTh7NT6yNkBvVQ>?	MmDqV2FPT0WU
NCI-H630	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILYTItKSzVyPUmxNk46PiCwTR?=	M{fWRnNCVkeHUh?=
Mo-T	NV32O3BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXhfnVvUUN3ME25OFcvQDhibl2=	MUnTRW5ITVJ?
JAR	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3OcXZOUUN3ME25OVYvOjRibl2=	M4XMXXNCVkeHUh?=
NCI-H1838	NVvKfnBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPYbIVkUUN3ME2xMlAzOzh6IN88US=>	M3\4[HNCVkeHUh?=
DoTc2-4510	NHzwV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTFwMEezO\|Yh\|ryP	NU\HfmxjW0GQR1XS
MKN28	NHf5fYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vGZmlEPTB;MT6wPVAzPCEQvF2=	MnnNV2FPT0WU
HuP-T3	NITVOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvyTWM2OD1zLkGxPVA2KM7:TR?=	M2\lbXNCVkeHUh?=
TE-9	NXG0TlhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;OSWlEPTB;MT6xNlk4OyEQvF2=	M33zbnNCVkeHUh?=
NY	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzLcZBbUUN3ME2xMlE3Pzl{IN88US=>	NYDtb\|V1W0GQR1XS
HT55	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwM{GzOFQh\|ryP	MnL3V2FPT0WU
SW837	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYWyN5V5UUN3ME2xMlMzQTd6IN88US=>	NW\ZeHc3W0GQR1XS
NCI-H2029	NGP1ZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fEd2lEPTB;MT60NVc6OSEQvF2=	NW\oZ2drW0GQR1XS
IST-SL1	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTFwNESyOEDPxE1?	Mk\KV2FPT0WU
COLO-741	NUW3[VZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHuTWM2OD1zLkS5O\|cyKM7:TR?=	MoPjV2FPT0WU
LU-65	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{L4N2lEPTB;MT62NlI1QSEQvF2=	NFL4flBUSU6JRWK=
NCI-H1304	NUTZVGtpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrKTWM2OD1zLk[1OFk5KM7:TR?=	MXvTRW5ITVJ?
KARPAS-299	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTETWM2OD1zLke5OFc6KM7:TR?=	M2\ab3NCVkeHUh?=
NCI-H358	M3j2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFwOUW1NFMh\|ryP	MYTTRW5ITVJ?
OAW-28	NHzUfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJwME[5NVkh\|ryP	MW\TRW5ITVJ?
C8166	M{fwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlv1TWM2OD1{Lk[zN\|kzKM7:TR?=	MkLqV2FPT0WU
COLO-678	NHXkcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1n6bmlEPTB;Mj64N\|c3QCEQvF2=	NWrFd4xOW0GQR1XS
SK-N-DZ	NEfReHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrvSopKSzVyPUKuPFY{QDFizszN	Mo\4V2FPT0WU
NCI-H82	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NImyTpNKSzVyPUKuPVA{PjlizszN	Mn\BV2FPT0WU
JVM-2	NWTG[\|FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4r6dGlEPTB;Mz6wN\|E5QCEQvF2=	M1\4ZnNCVkeHUh?=
SW1116	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorrTWM2OD1\|LkC1OFEyKM7:TR?=	NF;YU2hUSU6JRWK=
MDA-MB-453	M4Lj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnJTWM2OD1\|LkGwOFM6KM7:TR?=	M4HReHNCVkeHUh?=
Calu-6	NHzBS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvleZhwUUN3ME2zMlE6QTdizszN	Ml\GV2FPT0WU
SHP-77	NEHLXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nl[2lEPTB;Mz61Nlgh\|ryP	MkX2V2FPT0WU
Capan-2	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEW3eGlKSzVyPUSuN\|I2QDFizszN	M2fVd3NCVkeHUh?=
SW948	NU\CeJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PNVWlEPTB;ND63OFc4QSEQvF2=	NY\GNVl[W0GQR1XS
HDLM-2	M2GwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTVwMEe3NlUh\|ryP	NGHoNZVUSU6JRWK=
LAN-6	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFT6NWpKSzVyPU[uNlE1QTVizszN	NIXZZoFUSU6JRWK=
LU-135	MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTZwNEOwO\|ch\|ryP	M4LmdnNCVkeHUh?=
T84	NGLkenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zRT2lEPTB;Nj65PFY1KM7:TR?=	NV3E[Iw4W0GQR1XS
CAPAN-1	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrNTWM2OD15Lk[yNlM{KM7:TR?=	NVrPeYY1W0GQR1XS
SW1417	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7wOJJKSzVyPUeuPVE4OzFizszN	NH61c5hUSU6JRWK=
BALL-1	NXLJWoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4r4e2lEPTB;OD61NFQxQSEQvF2=	M37xSHNCVkeHUh?=
HT-29	NF7zcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\HUIxKSzVyPUmuNFc2QTlizszN	NVrNRW9pW0GQR1XS
C3A	M3y4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrYbppKSzVyPUmuPFg{QTRizszN	Mo\BV2FPT0WU
NCI-H1993	NGPX[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LzZ2lEPTB;MUCuOVA5OSEQvF2=	M3:zPXNCVkeHUh?=
SK-MEL-1	M4XRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnNVZp{UUN3ME2xNU43Ojh7IN88US=>	NX\wNZRnW0GQR1XS
DU-145	M33SUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnKWYFYUUN3ME2xOE42ODV{IN88US=>	NH;1[FNUSU6JRWK=
KP-N-YN	NEHGRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXrXIhlUUN3ME2xOE42OTB\|IN88US=>	NFzKeZBUSU6JRWK=
CCRF-CEM	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLkdXRKSzVyPUG0Mlc5ODlizszN	MXHTRW5ITVJ?
ZR-75-30	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTF4LkOzNFMh\|ryP	NEHwdpNUSU6JRWK=
A673	M1XrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTyTWM2OD1{MD61OVA4KM7:TR?=	NWXXU2ZTW0GQR1XS
K-562	NXPaUFlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoW4TWM2OD1{OD60NVg{KM7:TR?=	NEeyRXRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	+ Expand Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+polyethylene glycol 300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products5

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 143 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 143 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)